SEARL signs license agreement with Mabwell for biological medicines

MG News | July 12, 2023 at 03:09 PM GMT+05:00

0:00

July 12, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has entered into a License Agreement with Mabwell Pharmaceuticals, China, the latest company’s filing showed.

Under this agreement, the company will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan.

This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines.

“The company is committed to increasing its portfolio of products and business which will enhance the quality of its earnings and shareholders' value,” It reads.

Mabwell Pharmaceuticals is an innovative biopharmaceutical company.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	134,299.77 290.06M	0.39% 517.42
ALLSHR	84,018.16 764.12M	0.48% 402.35
KSE30	40,814.29 132.59M	0.33% 132.52
KMI30	192,589.16 116.24M	0.49% 948.28
KMIALLSHR	56,072.25 387.69M	0.32% 180.74
BKTi	36,971.75 19.46M	-0.05% -16.94
OGTi	28,240.28 6.19M	0.21% 58.78

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	118,140.00	119,450.00 115,635.00	4270.00 3.75%
BRENT CRUDE	70.65	70.71 68.55	2.01 2.93%
RICHARDS BAY COAL MONTHLY	97.50	0.00 0.00	1.10 1.14%
ROTTERDAM COAL MONTHLY	108.75	108.75 108.75	0.40 0.37%
USD RBD PALM OLEIN	998.50	998.50 998.50	0.00 0.00%
CRUDE OIL - WTI	68.75	68.77 66.50	2.18 3.27%
SUGAR #11 WORLD	16.56	16.60 16.20	0.30 1.85%